Clinical trials: Discontinuation
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Dementia
Cholinesterase Inhibitor Discontinuation
This study tries to determine if stopping certain medications that are used to treat dementia will cause worsening from the patient and family perspective.
- Trial name
- CID (NCT02248636)
- Testing
- Cholinesterase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- VA Office of Research and Development
Rheumatoid Arthritis
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01855789
- Testing
- Tocilizumab (TCZ), Methotrexate (MTX)
- Where
- 155 sites in United States
- Volunteers
- 718 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Osteoporosis
Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate
The study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after…
- Trial name
- PROSA (NCT03051620)
- Testing
- Discontinue alendronate
- Where
- Denmark
- Volunteers
- 142 people
- Sponsor
- Aarhus University Hospital
Chronic Graft Versus Host Disease
Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease.
- Trial name
- NCT03483675
- Testing
- Immunosuppressive Therapy, Survey Administration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells…
- Trial name
- ARTEMIS (NCT02474199)
- Testing
- darTregs, Acetaminophen, Diphenhydramine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, STI
Parrying the Pitfalls of PrEP: Project PEACH
The study is a prospective cohort of young MSM who are followed for 2 years either in-person at the PRISM Health Research Clinic and/or virtually with telehealth study visits.
- Trial name
- NCT05072093
- Testing
- PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Emory University
Erectile Dysfunction
A Study in Patients With Erectile Dysfunction
The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over…
- Trial name
- NCT01122264
- Testing
- Tadalafil, Sildenafil Citrate
- Where
- 45 sites in France, Germany and 6 more
- Volunteers
- 770 people
- Sponsor
- Eli Lilly and Company
Transplants and Implants
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant
The purpose of the study was to determine if rapid discontinuation of corticosteroids (also known as prednisone withdrawal) and maintenance immunosuppression with Prograf (tacrolimus) and CellCept (mycophenolate mofetil) while…
- Trial name
- NCT00596947
- Testing
- prednisone, rabbit antithymocyte globulin, Tacrolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
Severe Combined Immunodeficiency
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe combined immune deficiency (SCID) may result from inherited deficiency of the enzyme adenosine deaminase (ADA). Children with ADA-deficient SCID often die from infections in infancy, unless treated with either a bone…
- Trial name
- NCT00794508
- Testing
- ADA gene transfer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Donald B. Kohn, M.D.
Contraception Behavior
Premature Discontinuation of Contraceptive Implants
To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given…
- Trial name
- NCT04828824
- Testing
- Ethinyl Estradiol / Norgestimate Oral Tablet
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Colorectal Neoplasms, Melanoma
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
- Conditions
- Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma
- Trial name
- NCT00378482
- Testing
- CP-675,206 (Tremelimumab)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be…
- Trial name
- SIMPLIFY-DN (NCT06350474)
- Testing
- Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
- Where
- 81 sites in United States
- Volunteers
- 477 people
- Sponsor
- Nicole Hamblett
Multi-morbidity, Medication Therapy Management
Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care
Medication side effects and interactions between medications are very common in older adults and are related to negative health outcomes, including mobility.
- Conditions
- Multi-morbidity, Medication Therapy Management, Polypharmacy
- Trial name
- NCT03202264
- Testing
- TAPER
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McMaster University
Rheumatoid Arthritis
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
This study involves Rheumatoid Arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is intended to identify parameters that can…
- Trial name
- DOSERA (NCT00858780)
- Testing
- Etanercept
- Where
- 16 sites in Denmark, Finland and 4 more
- Volunteers
- 91 people
- Sponsor
- Pfizer
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Psoriasis
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
This is a pilot investigational study of the appropriate therapeutic regimens to treat subjects experiencing inflammatory recurrence (rebound) of psoriatic disease upon discontinuation of efalizumab therapy and of the biological…
- Trial name
- NCT01079988
- Testing
- Cyclosporins, Retinoids, Systemic corticosteroids
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Saracatinib in Treating Patients With Prostate Cancer
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01267266
- Testing
- saracatinib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)